Nuformix PLC Attendance at American Thoracic Society Congress

RNS Number : 1174J

Nuformix PLC

19 May 2025

 

Reach

 

19 May 2025

 

Nuformix plc

 

("Nuformix" or the "Company")

 

Attendance at the American Thoracic Society Congress 2025 and presentation of NXP002 data

 

Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce, its attendance at the American Thoracic Society Congress, taking place in San Francisco, USA, from 18 to 21 May 2025.

 

The positive results from the recent analysis of data from studies of NXP002 in a precision-cut lung slice ("PCLS") disease models using tissue from IPF and autoimmune ILD patients will be presented on 21 May within the Wednesday morning session titled "Drug Discovery and Development in IPF: Challenges and Opportunities".

 

Dr Dan Gooding, Executive Director, Nuformix, said: "We are delighted to be attending the ATS congress in San Francisco. We will have the opportunity to progress discussions with potential licensing and development partners and showcase the positive results from our recent analysis of NXP002's performance in tissue from multiple IPF and autoimmune ILD patients.  This follows the receipt of confirmation of eligibility for Orphan Drug Designation in IPF from the EMA.  I look forward to providing further updates in due course as appropriate."

 

Enquiries:

 

Nuformix plc
Dr Dan Gooding, Executive Director	Via IFC Advisory
CMC Markets
Douglas Crippen	[phone]
IFC Advisory Limited
Tim Metcalfe Zach Cohen	[phone] [e-mail]

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities.  Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

 

About IPF

 

IPF is a chronic lung disease characterised by progressive tissue scarring that prevents proper lung function. It is a progressive, fatal, age-associated lung disease affecting approximately three out of every one hundred thousand people in Europe. IPF typically presents in adults 65 or older and is usually fatal within two to five years after diagnosis.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAUWUNRVNUVAAR